Monopar Therapeutics Inc (MNPR)

$32.06 +0.22 (0.69%)
Market Cap 197.81M
Revenue (ttm) 0.00
Net Income (ttm) -15.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,800
Avg Vol 44,896
Day's Range N/A - N/A
Shares Out 6.17M
Stochastic %K 17%
Beta 1.05
Analysts Strong Sell
Price Target $60.40

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology
Sector: Healthcare
Phone: 847 388 0349
Address:
1000 Skokie Boulevard, Suite 350, Wilmette, United States
RadioIsotope25
RadioIsotope25 Aug. 22 at 2:37 AM
$RADX Biotech’s with LU-177 drugs that were acquired. Radiopharm has a pipeline flush of them and ceo is ex- Novartis. $MNPR $LNTH $CLRB
1 · Reply
uppalapatikc
uppalapatikc Aug. 18 at 4:18 PM
$MNPR This is the second time in a week that it got rejected at the 36.30 mark.
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 18 at 3:50 AM
$RADX Biotech Daily https://mcusercontent.com/2020b74e9b9a298e9cadee03b/files/86b90175-7040-d85a-e568-7d8751aa61b8/RAD_Aug_15_2025.pdf $MNPR $LNTH
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 14 at 6:10 PM
$RADX Could turn into to Corbus or MNPR 2.0 with strong data this fall Tiny float $MNPR $CRBP
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 8:59 PM
Chardan Capital has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 60.
0 · Reply
uppalapatikc
uppalapatikc Aug. 13 at 3:39 PM
$MNPR Wow what the hell is happening here, lost all of yesterdays gain
0 · Reply
uppalapatikc
uppalapatikc Aug. 12 at 5:50 PM
$MNPR I have been watching this stock for a while and finally decided to start a position yesterday. I have a feeling this is heading back to mid 40’s
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 12 at 2:54 PM
$RADX look forward to the readouts over the next few months. $LNTH $TLX $NVS $CATX $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 10 at 1:09 AM
$RADX $30 target @ Jones Research $MNPR $LNTH $ATNM
2 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 6:11 PM
$MNPR Excellent article that nails exactly where MNPR stands right now. So if you want to update your MNPR knowledge or get acquainted with MNPR, this is a must read. https://beyondspx.com/article/monopar-therapeutics-a-dual-pipeline-bet-on-rare-disease-and-radiopharmaceuticals-nasdaq-mnpr
0 · Reply
Latest News on MNPR
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Aug 12, 2025, 8:00 AM EDT - 11 days ago

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Jun 11, 2025, 7:00 AM EDT - 2 months ago

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025, 8:00 AM EDT - 3 months ago

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025, 2:30 AM EDT - 3 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Jan 23, 2025, 1:10 PM EST - 7 months ago

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Dec 23, 2024, 2:23 PM EST - 8 months ago

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 20, 2024, 9:00 AM EST - 8 months ago

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Dec 5, 2024, 4:21 PM EST - 9 months ago

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 9 months ago

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Nov 25, 2024, 7:53 PM EST - 9 months ago

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Nov 8, 2024, 8:00 AM EST - 10 months ago

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Oct 30, 2024, 1:42 PM EDT - 10 months ago

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024, 9:15 PM EDT - 10 months ago

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 4:00 PM EDT - 10 months ago

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Oct 28, 2024, 1:29 PM EDT - 10 months ago

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Oct 24, 2024, 1:18 PM EDT - 10 months ago

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

AZN

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Oct 22, 2024, 8:00 AM EDT - 10 months ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Oct 15, 2024, 8:00 AM EDT - 11 months ago

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Aug 21, 2024, 8:00 AM EDT - 1 year ago

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Monopar and NorthStar Amend & Extend Collaboration

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Monopar Announces CFO Succession

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

May 9, 2024, 7:00 AM EDT - 1 year ago

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Mar 5, 2024, 7:00 AM EST - 1 year ago

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Feb 27, 2024, 7:00 AM EST - 1 year ago

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Feb 20, 2024, 8:00 AM EST - 1 year ago

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Nov 9, 2023, 7:00 AM EST - 1 year ago

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Oct 10, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Jun 21, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

Jun 14, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

May 11, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

Monopar to Present at the Jefferies Radiopharma Innovation Summit

Mar 28, 2023, 7:00 AM EDT - 2 years ago

Monopar to Present at the Jefferies Radiopharma Innovation Summit

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

Mar 27, 2023, 5:00 PM EDT - 2 years ago

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Monopar to Present at the 35th Annual Roth Conference

Mar 7, 2023, 7:00 AM EST - 2 years ago

Monopar to Present at the 35th Annual Roth Conference

Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

Feb 27, 2023, 7:00 AM EST - 2 years ago

Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

RadioIsotope25
RadioIsotope25 Aug. 22 at 2:37 AM
$RADX Biotech’s with LU-177 drugs that were acquired. Radiopharm has a pipeline flush of them and ceo is ex- Novartis. $MNPR $LNTH $CLRB
1 · Reply
uppalapatikc
uppalapatikc Aug. 18 at 4:18 PM
$MNPR This is the second time in a week that it got rejected at the 36.30 mark.
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 18 at 3:50 AM
$RADX Biotech Daily https://mcusercontent.com/2020b74e9b9a298e9cadee03b/files/86b90175-7040-d85a-e568-7d8751aa61b8/RAD_Aug_15_2025.pdf $MNPR $LNTH
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 14 at 6:10 PM
$RADX Could turn into to Corbus or MNPR 2.0 with strong data this fall Tiny float $MNPR $CRBP
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 8:59 PM
Chardan Capital has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 60.
0 · Reply
uppalapatikc
uppalapatikc Aug. 13 at 3:39 PM
$MNPR Wow what the hell is happening here, lost all of yesterdays gain
0 · Reply
uppalapatikc
uppalapatikc Aug. 12 at 5:50 PM
$MNPR I have been watching this stock for a while and finally decided to start a position yesterday. I have a feeling this is heading back to mid 40’s
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 12 at 2:54 PM
$RADX look forward to the readouts over the next few months. $LNTH $TLX $NVS $CATX $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 10 at 1:09 AM
$RADX $30 target @ Jones Research $MNPR $LNTH $ATNM
2 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 6:11 PM
$MNPR Excellent article that nails exactly where MNPR stands right now. So if you want to update your MNPR knowledge or get acquainted with MNPR, this is a must read. https://beyondspx.com/article/monopar-therapeutics-a-dual-pipeline-bet-on-rare-disease-and-radiopharmaceuticals-nasdaq-mnpr
0 · Reply
IsabellaDC
IsabellaDC Jul. 29 at 4:52 PM
Swing trades possible with these RUSS stocks. Be patient with your entries. $QUBT $QBTS $PRCH $SEZL $MNPR and so on.
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 25 at 6:41 PM
Australian radiopharmaceutical market is hot Clarity Pharmaceuticals market cap just tripled to $920 million and Telix Market cap is $4.7 billion. Makes Radiopharma Theranostics looks very cheap at $35 million market cap. Imaging data out soon could be next big winner. $RADX $MNPR $LNTH $IOVA
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 20 at 2:45 PM
Her2 Lu-177 is showing 30-40% responses in other similar trials. Should provide great upside to RADX 3q data $RADX $LNTH $MNPR
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 18 at 2:34 PM
$CYCN there's a group of about 5 or 6 us longs in here that own over 10% of the company collectively, the former CEO and current chairman of the board, Peter Hecht, owns 30% himself. Other insiders own around 10%. Tutes then own another 20-30%. This thing has very little free float so when the news hammer gets dropped (any day now), this thing will be of epic proportions. Think $DRUG or $MNPR type move IMO
0 · Reply
IanMaui
IanMaui Jul. 18 at 1:47 PM
$MNPR back to $50! Still a holder!
1 · Reply
stockbott
stockbott Jul. 17 at 9:08 PM
$MNPR going up. 50$
0 · Reply
Doozio
Doozio Jul. 17 at 6:45 PM
$MNPR until they weren’t. Bahhht out of🐑⏰♾️ they are. 🐒🍌🧠⏰♾️
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 10 at 4:09 PM
$RADX Only 4K borrow could explode at any time in Radiopharm Theranostics $MP $NNE $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 8 at 6:42 PM
$RADX Trading at $4.00 And that’s a $7.70 discount to what Lantheus just paid in January. https://m.youtube.com/watch?v=OjzgnRS7b98 $MNPR $NNE
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 8:28 PM
Cantor Fitzgerald has updated their rating for Monopar Therapeutics ( $MNPR ) to Overweight with a price target of 74.
0 · Reply
JarvisFlow
JarvisFlow Jun. 23 at 11:00 AM
Chardan Capital has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 60.
0 · Reply
wavess
wavess Jun. 18 at 6:29 PM
$TTIPF Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has activated its second clinical site in France for the Phase 2 trial of TTI-0102, a next-gen thiol-based therapy for MELAS—a rare and devastating mitochondrial disease: https://x.com/StckMasterFlash/status/1935049659816214802 On track for key data readouts by September 2025, this expansion highlights both the growing momentum behind TTI-0102 and the strategic advantage of conducting trials in Europe’s increasingly efficient regulatory landscape for orphan diseases, over the US FDA. $MNPR $XENE
0 · Reply